Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.50 |
| ▸ | BACE1 | P56817 | 2/20 | 0.45 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | CPA1 | P15085 | 1/20 | 0.43 |
| ▸ | CPA2 | P48052 | 1/20 | 0.43 |
| ▸ | CPA4 | Q9UI42 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12522504 | 0.82 | CASP1 (0.54) | CASP1BACE1BACE2HRH1REN | |
| SCHEMBL14369991 | 0.82 | CASP1 (0.54) | CASP1BACE1BACE2HRH1REN | |
| SCHEMBL949558 | 0.82 | CASP1 (0.54) | CASP1BACE1BACE2HRH1REN | |
| SCHEMBL949560 | 0.78 | CASP1 (0.45) | CASP1BACE1BACE2CPA1CPA2 | |
| SCHEMBL2314756 | 0.78 | CASP1 (0.61) | CASP1BACE1BACE2CPA1CPA2 | |
| SCHEMBL2314769 | 0.78 | CASP1 (0.61) | CASP1BACE1BACE2CPA1CPA2 | |
| SCHEMBL14370014 | 0.77 | CASP1 (0.60) | CASP1BACE1BACE2RENCPA1 | |
| SCHEMBL9241543 | 0.76 | CASP1 (0.67) | CASP1BACE1BACE2OPRD1 | |
| SCHEMBL27825824 | 0.76 | CASP1 (0.67) | CASP1BACE1BACE2OPRD1 | |
| SCHEMBL29030118 | 0.75 | CASP1 (0.64) | CASP1BACE1BACE2OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7288624-B2 | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-30 | — | — | US | disclosed |
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | VERTEX PHARMACEUTICALS INCORPORATED | 2002-07-25 | — | — | US | disclosed |
| US-5847135-A | Inhibitors of interleukin-1β converting enzyme | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099042-A1 | Inhibitors of interleukin-1 beta converting enzyme | IL1B, IL1A, IL1RN | CASP1 6/4885BACE1 12/4885BACE2 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.